Monday, September 13, 2021

Why Regenxbio Stock Is Way Up Today | Nasdaq

Upfront, AbbVie will pay Regenexbio $370 million for rights to RGX-314, an experimental gene therapy for the treatment of progressive retinal ...

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

2 muggers captured by RU students on campus - UNB

Rayhanul Ferdous, a student of Genetic Engineering and Biotechnology department who had his phone stolen told UNB: “I was walking on the eas...